McKesson Corporation v. Benzer Pharmacy Holding LLC

CourtDistrict Court, M.D. Florida
DecidedDecember 2, 2020
Docket8:20-cv-02186
StatusUnknown

This text of McKesson Corporation v. Benzer Pharmacy Holding LLC (McKesson Corporation v. Benzer Pharmacy Holding LLC) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
McKesson Corporation v. Benzer Pharmacy Holding LLC, (M.D. Fla. 2020).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION

MCKESSON CORPORATION,

Plaintiff,

v. Case No: 8:20-cv-2186-T-33AAS

BENZER PHARMACY HOLDING LLC, BENZER NV 1 LLC, ALPESH PATEL and HEMA PATEL,

Defendants. ____________________________/

ORDER This matter comes before the Court upon consideration of Plaintiff and Counterclaim-Defendant McKesson Corporation’s partial Motion to Dismiss Counterclaim (Doc. # 20), filed on November 4, 2020. Defendants and Counterclaim-Plaintiffs Benzer Pharmacy Holding LLC, Benzer NV 1 LLC, Alpesh Patel, and Hema Patel (collectively, the “Benzer Parties”) responded on November 18, 2020. (Doc. # 22). For the reasons below, the Motion is granted in part. I. Background The Benzer Parties operate pharmacies in the United States and have contracted with McKesson, a supplier of pharmaceutical drugs, since 2010. (Doc. # 17 at 22-23). In October 2016, the Benzer Parties entered into a supply agreement (the “Agreement”) with McKesson, which is the subject of this suit. (Id. at 23). In pertinent part, the Agreement includes the following reservation clause: McKesson reserves the right, in its sole discretion, to change a payment term (including imposing cash payment on delivery), to limit total credit and/or to suspend or discontinue the shipment of any orders to [the Benzer Parties] if McKesson concludes that (I) there has been a material adverse change in the [Benzer Parties’] financial condition or payment performance or (II) [the Benzer Parties have] ceased or [are] likely to cease to meet McKesson’s credit requirements.

(Id. at 24). Additionally, the “Agreement carried significant penalties for any late payments.” (Id.). The parties also had certain customary dealings apart from the Agreement. (Id. at 23-24). For example, “it was customary for McKesson to issue invoices from Saturday through Friday that would be payable the Friday of the third following week.” (Id. at 23). Because the Benzer Parties purchased significant amounts of pharmaceutical products from McKesson, these “payment terms had a significant impact” on the Benzer Parties’ cash flow. (Id. at 24). In early 2019 – about three years after the parties entered into the Agreement – the business relationship began deteriorating. (Id.). The Benzer Parties allege that McKesson began interfering with their business in a number of ways. First, McKesson allegedly “sent a letter to [a competing] supplier for the sole purpose of persuading the supplier that it was at risk of a claim from McKesson if it did business with the Benzer Parties.” (Id.). Next, after the Benzer Parties began discussing getting acquired by another entity, McKesson allegedly “disparaged the Benzer Parties to [the] potential acquirer,” which caused “the acquirer to lose interest in the transaction and cease negotiations with the Benzer Parties.” (Id. at 26).

Apart from this alleged meddling in the Benzer Parties’ dealings with third parties, “McKesson also began arbitrarily [and unilaterally] changing its established course of conduct with the Benzer Parties.” (Id. at 24). For instance, “[i]n February 2019, McKesson changed its policy so that, if one of the Benzer Parties or any of their affiliates failed to make a payment on time, it put the accounts of all . . . Benzer Parties on hold.” (Id.). McKesson also “began demanding repayment of loans, despite such loans not being due,” and “refused to subordinate its position in the Benzer Parties’ accounts receivable” which prevented the Benzer Parties from accessing a $7.5 million line of credit. (Id. at 26).

Furthermore, in July 2019, without reason, and with only one week’s notice, “McKesson demanded that payments under the . . . Agreement be made on the Tuesday of the third week following the date of the invoice, as opposed to the Friday date previously used by the parties.” (Id. at 25). The Benzer Parties aver that these changes in McKesson’s payment terms “significant[ly] impact[ed] . . . [their] cash flow and operations.” (Id.). Namely, these changes “limit[ed] the amount of product that the Benzer Parties could order, the Benzer Parties were not able to meet all of their customers’ needs,” and the Benzer Parties suffered “a significant loss

in revenue.” (Id.). And, under these new terms, McKesson “began charging late fees.” (Id.). McKesson would then apply “the Benzer Parties’ payments to [the] late fees, rather than to payment of amounts incurred for pharmaceutical supplies.” (Id. at 26). McKesson initiated the underlying suit on September 16, 2020, alleging various breach-of-contract claims. (Doc. # 1). On October 14, 2020, the Benzer Parties filed their answer and counterclaim. (Doc. # 17). The counterclaim includes claims against McKesson for breach of contract (Count I), breach of the implied duty of good faith and fair dealing (Count II), violation of the Florida Deceptive and Unfair

Trade Practices Act (“FDUTPA”) (Count III), accounting (Count IV), declaratory judgment (Count V), tortious interference with a business relationship (Count VI), and tortious interference with a business expectancy (Count VII). (Id.). On November 4, 2020, McKesson moved to dismiss Counts II, III, V, and VI of the counterclaim for failure to state a claim, as well as for partial dismissal of Count VII. (Doc. # 20). In the alternative, McKesson moves for the Court to strike Count VII. (Id.). The Benzer Parties have responded (Doc. # 22), and the Motion is now ripe for review. II. Legal Standard

On a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), this Court accepts as true all the allegations in the counterclaim and construes them in the light most favorable to the plaintiff. Jackson v. Bellsouth Telecomms., 372 F.3d 1250, 1262 (11th Cir. 2004). Further, the Court favors the counterclaim-plaintiff with all reasonable inferences from the allegations in the counterclaim. Stephens v. Dep’t of Health & Human Servs., 901 F.2d 1571, 1573 (11th Cir. 1990). But, [w]hile a [counterclaim] attacked by a Rule 12(b)(6) motion to dismiss does not need detailed factual allegations, a [counterclaim-plaintiff’s] obligation to provide the grounds of his entitlement to relief requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do. Factual allegations must be enough to raise a right to relief above the speculative level. Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (quotations and citations omitted). Courts are not “bound to accept as true a legal conclusion couched as a factual allegation.” Papasan v. Allain, 478 U.S. 265, 286 (1986). The Court must limit its consideration to “well-pleaded factual allegations, documents central to or referenced in the [counterclaim], and matters judicially noticed.” La Grasta v. First Union Sec., Inc., 358 F.3d 840, 845 (11th Cir. 2004). III. Analysis McKesson seeks dismissal of Counts II, III, V, and VI of the counterclaim, along with Count VII to the extent that it purports to “state a claim for tortious interference with unidentified customers.” (Doc. # 20 at 1-2). Alternatively, McKesson moves the Court to strike Count VII. (Id.). The Court

will address each claim in turn. A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burger King Corp. v. Weaver
169 F.3d 1310 (Eleventh Circuit, 1999)
Sandra Jackson v. BellSouth Telecommunications
372 F.3d 1250 (Eleventh Circuit, 2004)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Jean Resnick v. AvMed, Inc.
693 F.3d 1317 (Eleventh Circuit, 2012)
Ethan Allen, Inc. v. Georgetown Manor
647 So. 2d 812 (Supreme Court of Florida, 1994)
Kertesz v. Net Transactions, Ltd.
635 F. Supp. 2d 1339 (S.D. Florida, 2009)
Rebman v. Follett Higher Education Group, Inc.
575 F. Supp. 2d 1272 (M.D. Florida, 2008)
Rollins, Inc. v. Butland
951 So. 2d 860 (District Court of Appeal of Florida, 2006)
County of Brevard v. Miorelli Engineering
703 So. 2d 1049 (Supreme Court of Florida, 1997)
City First Mortg. Corp. v. Barton
988 So. 2d 82 (District Court of Appeal of Florida, 2008)
PNR, Inc. v. Beacon Property Management, Inc.
842 So. 2d 773 (Supreme Court of Florida, 2003)
Medmarc Casualty Insurance v. Pineiro & Byrd PLLC
783 F. Supp. 2d 1214 (S.D. Florida, 2011)
Bookworld Trade, Inc. v. Daughters of St. Paul, Inc.
532 F. Supp. 2d 1350 (M.D. Florida, 2007)
Shibata v. Lim
133 F. Supp. 2d 1311 (M.D. Florida, 2000)
Procentury Insurance v. Harbor House Club Condominium Ass'n
652 F. Supp. 2d 552 (D. New Jersey, 2009)
Knights Armament Co. v. Optical Systems Technology, Inc.
568 F. Supp. 2d 1369 (M.D. Florida, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
McKesson Corporation v. Benzer Pharmacy Holding LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mckesson-corporation-v-benzer-pharmacy-holding-llc-flmd-2020.